Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Wuzhi Capsule (WZC) is a traditional Chinese medicinal herb widely used to treat drug-induced hepatitis or liver dysfunction and is usually prescribed in China to increase tacrolimus concentration. Several studies with small sample sizes have shown that WZC can increase tacrolimus concentration levels in clinical practice. This study aimed to evaluate the effect of WZC on whole-blood tacrolimus concentration levels and safety.
Methods: We searched 7 databases for randomized clinical trials (RCTs) and observational studies (OSs) comparing whole-blood tacrolimus concentration levels between WZC and non-WZC treatments. Data analysis was performed using Review Manager version 5.3. This study was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines.
Results: Eleven studies involving 6 RCTs and 5 OSs were included. The meta-analysis indicated that whole-blood tacrolimus concentration levels in the WZC group was significantly higher than that of the non-WZC group [weighted mean difference = 1.38, 95% CI (confidence interval), 1.21-1.56, P < 0.001], and similar results were shown in all the subgroups of follow-up time, different primary disease, and different WZC doses. In the self-control OSs, the whole-blood tacrolimus concentration levels in the WZC group was significantly higher than the non-WZC group (weighted mean difference = 1.17, 95% CI, 0.71-1.64, P < 0.001). WZC was generally well tolerated and there was no significant difference in the incidence of adverse reactions between the 2 groups.
Conclusions: WZC can increase whole-blood tacrolimus concentration levels. This may be an economical and practical treatment choice for patients, especially those with poor oral tacrolimus absorption capabilities. Nevertheless, RCTs and OSs with large sample sizes and high quality are needed in the future to confirm these positive results.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10769163 | PMC |
| http://dx.doi.org/10.1097/FTD.0000000000001155 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Accurate tacrolimus monitoring by dual peripherally inserted central catheters in allogeneic HSCT.
Int J Hematol
September 2025
Department of Hematology and Oncology, Asahikawa Red Cross Hospital, 1-1 Akebono-Cho, Asahikawa, Hokkaido, Japan.
Introduction: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) requires reliable vascular access for medication, transfusion, and blood sampling, which often involves painful venipuncture. This prospective study evaluated a novel dual peripherally inserted central venous catheter (PICC) technique to reduce venipuncture frequency in allo-HSCT recipients.
Methods: The study enrolled 29 allo-HSCT recipients.
Tacrolimus-Loaded Superabsorbent Hydrogels: Formulation, Evaluation, and Therapeutic Potential.
ACS Omega
September 2025
Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, P.O. Box 84428, Riyadh 11671, Saudi Arabia.
Tacrolimus belongs to the BCS class-II drug family and exhibits poor water solubility, which leads to poor bioavailability. Furthermore, since tacrolimus is an immunosuppressant, it is essential to maintain its therapeutic concentration for a greater period of time to confirm its effectiveness against transplant rejection. Therefore, to achieve the objective of the sustained release of the drug with a suitable amount of entrapment efficiency, pH-sensitive tacrolimus-loaded superabsorbent hydrogels using chitosan have been prepared.
View Article and Find Full Text PDFGut microbiota and metabolites related intra-patient variability of tacrolimus pharmacokinetics predicted adverse one-year outcomes following kidney transplantation.
Int Immunopharmacol
September 2025
Transplantation Center, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Key Laboratory of Translational Research in Transplantation Medicine of National Health Commission, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, China; Clinical Resea
Kidney transplantation (KT) is an effective treatment for end-stage renal disease, with over 90 % of recipients requiring lifelong tacrolimus (Tac). However, The Tac pharmacokinetics exhibit high intra-patient variability (IPV), posing significant challenges. This study included 102 KT recipients at our center from October 2022 to December 2023.
View Article and Find Full Text PDFConcentration-dependent blood binding: assessing implications through physiologically based Pharmacokinetic modeling of tacrolimus as a case example.
J Pharmacokinet Pharmacodyn
September 2025
Centre for Applied Pharmacokinetic Research (CAPKR), University of Manchester, Manchester, UK.
Concentration-dependent binding to red blood cells is a characteristic of several drugs, complicating the understanding of how pathophysiological factors influence drug behavior. This study utilized user-friendly, physiologically-based pharmacokinetic (PBPK) models to compare concentration-dependent and independent blood-to-plasma drug concentration ratios (B/P), using tacrolimus as a case study. Two models were developed and validated for tacrolimus using clinical data from healthy volunteers; Model 1 accounted for saturable blood binding, and Model 2 used a constant B/P level.
View Article and Find Full Text PDFEffects of routes, concentrations and genetic polymorphisms on posaconazole-tacrolimus interactions in allogeneic haematopoietic cell transplantation.
Br J Clin Pharmacol
September 2025
Preventive Medicine and Environmental Health, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.
There is no prospective research on factors influencing posaconazole (PSCZ)-tacrolimus (TAC) interactions. This prospective observational study analysed 30 allogeneic haematopoietic cell transplantation recipients: 19 started PSCZ while receiving oral (n = 10) or intravenous (IV) TAC (n = 9) and 11 switched from IV to oral TAC during PSCZ administration. Following PSCZ initiation, the median TAC dose reductions were 45% for oral and 39% for IV TAC.
View Article and Find Full Text PDF